Search:

2020 National Adult and Influenza Immunization Summit Virtual Meeting

Impact of COVID-19 on Adult Immunization Coverage Rates and Update from CDC on Influenza Communications for 2020-21

July 30, 2020 | 9:00-11:00 am, CST

The data showing the dramatic impact of COVID-19 in reducing routine pediatric immunization coverage rates are clear. At this virtual meeting, 6 vaccine manufacturers will present their data on the impact of COVID-19 on adult immunization coverage rates in the United States and internationally. Presentations will also include information on potential directions that manufacturers will take in the fall to address the steep decline in adult immunization coverage rates. Additionally, Becton-Dickinson will be presenting on their work to ensure a stable supply chain of syringes and needles and CDC will present information on CDC communications for the upcoming influenza season.

Tentative Agenda

  • Welcome by NAIIS leaders
  • Update from CDC on communications for the 2020-21 influenza season
  • Data presentations by six manufacturers on impact of COVID-19 on adult immunization coverage rates. Scheduled to present are (Seqirus, Sanofi Pasteur, Pfizer, Merck, GSK, and AstraZeneca)
  • Ensuring a supply of syringes and needles for routine and COVID-19 vaccinations (Becton Dickinson)
  • Summit questions and answers to the Panel
Registration closes at 3:00pm EST on Wednesday July 29, 2020
Impact of COVID-19 on Adult Immunization Coverage Rates and Update from CDC on Influenza Communications for 2020-21 ________________________________________________________________________

Influenza Prevention in the Era of COVID-19

May 21, 2020

Because the annual in-person National Adult and Influenza Immunization Summit meeting was cancelled in response to COVID-19 recommendations, a virtual Summit meeting was held on May 21, 2020. With its focus on influenza, the virtual meeting mirrored the typical final day of the in-person Summit. Please check below to view a recording of the entire virtual event, access individual presentations shared during the meeting, or review questions and answers provided by the presenters.

Influenza Prevention in the Era of COVID-19 Vaccine

 

SESSION ONE: Opening and CDC Influenza Updates

 

  • Opening Welcome
    L.J Tan, MS, PhD
    Chief Strategy Officer
    Immunization Action Coalition (IAC)
    Ilka Chavez, MPA
    Senior Public Health Advisor, Office of Infectious Disease and HIV/AIDS Policy
    Department of Health and Human Services (OIDP-HHS)
  • Setting the Stage (no slides)
    Nancy Messonnier, MD
    Director, National Center for Immunizations and Respiratory Diseases
    Centers for Disease Control and Prevention (CDC)
  • ACIP Influenza Update
    Lisa Grohskopf, MD, MPH
    Medical Officer, Influenza Division
    Centers for Disease Control and Prevention (CDC)

 

SESSION TWO: Partner Organization Updates

 

  • Adult IIS Project
    Rebecca Coyle, MSEd
    Executive Director
    American Immunization Registry Association (AIRA)
  • 2020–2021 AAFP Influenza Plan
    Amy Mullins, MD
    Medical Director, Quality and Science
    American Academy of Family Physicians (AAFP)
    Bellinda Schoof, MHA, CPHQ, CAE
    Director, Health of the Public and Science
    American Academy of Family Physicians (AAFP)
    Pamela Carter-Smith, MPA
    Clinical Policies Strategist, Health of the Public and Science
    American Academy of Family Physicians (AAFP)
  • Influenza Update
    Flor Munoz, MD, FAAP
    Associate Professor of Pediatrics,
    Infectious Diseases, Molecular Virology, and Microbiology
    Baylor College of Medicine,
    American Academy of Pediatrics (AAP)
  • ACP Update
    Selam Wubu, MPH
    Director, Center for Quality
    American College of Physicians (ACP)

 

SESSION THREE: Influenza Vaccine Manufacturer Updates

 

  • Closing Remarks (no slides)
    L.J Tan, M.S, PhD
    Chief Strategy Officer
    Immunization Action Coalition (IAC)

(to be posted soon)
Questions and Answers from the presenters

________________________________________________________________________

Developing COVID-19 Vaccines in Record Time: Platforms and Partnerships for Prevention

May 12, 2020

Global health leaders have all said that the long-term solution to ending the pandemic is the arrival of a vaccine or vaccines that can be rapidly deployed around the world. Yet the development of a vaccine is a complex undertaking, especially during a global pandemic of an unknown pathogen with uncertain epidemiology. Even so, many vaccine developers moved swiftly, using platform technologies to go from genetic sequence data to vaccine candidates in a few short weeks, shortening typical timelines by months and years.

During this virtual meeting, the panel members shown below discussed the path to clinical trials and shared their thoughts on how collaboration will bring life-saving vaccines to the world in this time of unprecedented need.

Please check below to view a recording of the entire panel discussion or to access individual presentations shared during the meeting.

Developing COVID-19 Vaccines in Record Time

PANELISTS

 

  • Introduction
    Phyllis Arthur, MBA
    Vice President, Infectious Diseases & Diagnostics Policy
    BIO

 

Search: